Lili Yang
Impact in
- Immunology top 5%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Papers in
- Immunology 43
- Immune Cell Function and Interaction 20
- Immunotherapy and Immune Responses 15
- Immune cells in cancer 8
- T-cell and B-cell Immunology 7
- Oncology 40
- Cancer Immunotherapy and Biomarkers 13
- CAR-T cell therapy research 8
Lili Yang
105 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 125
- Immunology 733
- Cancer Research 496
- Oncology 616
- Molecular Biology 944
- Hematology 140
Countries citing papers authored by Lili Yang
This map shows the geographic impact of Lili Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lili Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lili Yang more than expected).
Fields of papers citing papers by Lili Yang
This network shows the impact of papers produced by Lili Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lili Yang. The network helps show where Lili Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lili Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 2 | |
| 4 | 2025 | 0 | |
| 5 | 2024 | 2 | |
| 6 | 2023 | 4 | |
| 7 | 2023 | 6 | |
| 8 | 2023 | 3 | |
| 9 | 2023 | 38 | |
| 10 | 2022 | 11 | |
| 11 | 2022 | 12 | |
| 12 | 2021 | 37 | |
| 13 | MicroRNA-375 Targets ATG14 to Inhibit Autophagy and Sensitize Hepatocellular Carcinoma Cells to Sorafenib | 2020 | 1 |
| 14 | 2019 | 14 | |
| 15 | 2019 | 4 | |
| 16 | 2016 | 9 | |
| 17 | 2014 | 19 | |
| 18 | 2013 | 22 | |
| 19 | 2010 | 0 | |
| 20 | Clinical Effects of Administering Dendritic Cells and Cytokine Induced Killer Cells Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | 2009 | 3 |
About Lili Yang
Lili Yang is a scholar working on Immunology, Oncology, Cancer Research, Biological Psychiatry and Hematology, having authored 112 papers that have together received 2.1k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (20 papers), Immunotherapy and Immune Responses (15 papers), Cancer Immunotherapy and Biomarkers (13 papers), RNA modifications and cancer (8 papers), CAR-T cell therapy research (8 papers), Epigenetics and DNA Methylation (8 papers), Immune cells in cancer (8 papers) and T-cell and B-cell Immunology (7 papers). The work is most often cited by research in Immunology (733 citations), Cancer Research (496 citations), Oncology (616 citations), Molecular Biology (944 citations) and Hematology (140 citations). Lili Yang has collaborated with scholars based in China, United States and France. Frequent co-authors include Xiubao Ren, Lei Wu, Feng Wei, Baihui Li, Jian Wang, Qiurong Ruan, Jinpu Yu, Xinwei Zhang, Jingwu Li and Junling Shen. Their work appears in journals such as Oncotarget, Frontiers in Immunology, Cancer Biology and Medicine, The Journal of Immunology and OncoImmunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.